New TB vaccine could enter clinical trials within two years
LONDON – A candidate vaccine to protect against tuberculosis can protect mice against the disease at least as well as the current vaccine in use, the live bacillus Calmette-Guérin (BCG). Importantly, the vaccine does not include two antigens that are used in current diagnostic tests, called ESAT-6 and CFP10, as this would make it impossible to tell whether someone was infected or had simply been vaccinated. Claus Aagaard, senior scientist at the Staten Serums Institute in Copenhagen, Denmark, told BioWorld Today, “We hope to start clinical trials within two years."
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter